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Prevention of metastasis from mouse mammary carcinomas with
liposomes carrying doxorubicin
J Vaage', D Donovan', T Loftus' and P Working2
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S_q Weekly ents with doxorubicin sated in long crculaing, sterically stabised liposomes
(DOX-SL) redIued the i of metasases from primary mammary cnomas from 24 of 47 untreated
mice to 3 of 23 treated mice. Tonc side-effects were limited to mior, trant weaght losses.
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The therapeutic efficacy of doxorubicin was found to be
increased and its toxic sidefects reduced (Vaa et al.,
1993) when the drugs were encapsulated in liposomes that
had polyethylene glycol conjugated to one of the lipids,
producing smaller liposomes with greater membrane rigidity
and a negative net surface charge (sterically stabiised
liposomes) (Gabizon and Papahadiopoulos, 1988; Allen et
al., 1991). These liposomes have been given the trade name
Stealth Liposomes (SL) because of their reduced uptake by
the reticuloendothelial system (Lasic et al., 1991) and their
long (>20h in mice) crculation half-life (Allen et al., 1991).
The purpose of this investigation was to determine the
tastasis-preventive effects of i.v. injections of doxorubicin
in SL (DOX-SL) at an easily tolerated weekly treatment
schedule. The chemopreventtve injections were started when
the tumours were 0.1-0.2 cm3, and likcely to he shdding cells
into the ciculation. Because of the high mortality resulting
after more than I month of weekly i.v. injections of doxo-
rubicin in the free form (data not shown), a direct com-
parison with DOX-SL of the prophylactic effects of the free
drug was not possible.
Materials aJd ithod
Tunours
Breeding femal C3H/He mice have a high incidence of
spontaneous mammary carcinomas. The median age at
tumour development is 268 days, with a range of 173-530
days (Vaage et al., 1986). About half of the tumours will
produce pulmonary metastases in the original host (Vaage
and Harlos, 1987). Tumours were measured weekly and the
volumes determined by the formula 0.4 (ab2), where a is the
larger and b the maller diameter.
Liposome components
The liposome components were: cholesterol (Croda, Fuller-
ton, CA, USA) hydrogenated soy phosphatidylcholine
(HSPC; Lipoid KG, Ludwigshafen, Germany), and dist-
earoylphosphatidylethanolamine (DSPE; Genzyme, Camb-
ridge, MA, USA) conjugated at its amino position with a
1900 molcular weight segment of methoxypolyethyklne
glycol carbamate ofDSPE (MPEG-1900-DSPE) (Alen et al.,
1991).
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Test materials
DOX-SL and non-liposomal doxorubicin (Adriamycin RDF,
2.0mgml', Farmitalia Carlo Erba, Milan, Italy) were pro-
vided by Liposome Technology, (Menlo Parrk, CA, USA).
Doxorubicin concentration was 2.0mgml-', drug encapsula-
tion eficiency was>90%, and the mean particle size was
96nm. The ratio of drug to lipid was 1:8. Control mice
r ived saline.
Treatment schedules
The weights ofthe mice were recorded weekly from the day a
tumour was first detected. The mean weight at the start of
treatment was 29.5 ± 0.7 (s.em.) g, range 24-34 g. Weekly
prophylactic tail-vein injections of 6mgkg-' DOX-SL were
started when the progr growth of a tumour was
verified, at an average size of 0.2cm3. Tumours were excised
when they rhed a volume of 0.8-1.0cm3, at which time
the treatments were stopped. Following tumour excision, a
mouse was seected for euthanasia by carbon dioxide asphyx-
iation when it appeared to be in poor health, or no later than
6 weeks after surgery. All mice were necropsied, and the
visceral organs removed. The lungs were examined for metas-
tases by taing four stepwise, 5 pm sections of each of the
five lobes. The quantity of metastases per mouse was graded
on a scale of 0-5 shown in Table I.
Resdks
The results presented in Table H show that weekly injections
of 6mgkg-' DOX-SL effectively inhibited the development
of metastases from mammary carcinomas (X = 7.9, P<
0.005) and prolonged mean survival from 59 days in the
placebo group to 88.7 days in the treated group (t = 3.53,
P<0.001). The tumours in untreated mice grew progress-
ively, and were surgically removed, 17 ± 0.6 days after detec-
tion, at an average size of 0.9 ± 0.08 cm3. In the treated mice
Table I Quantitative grading ofpuhmonary metastasesa
0 = no metastases found by histologial examination
1 = 1-3 small metasta ( <0.1 mm diameter)
2 = 4-10 small or medium (0.2-0.3 mm) metastases
3 = >10 small or 2-5 medium or one large (0.4-1.0 mm) metastases
4 = > 5 medium or >2 large metastases
5 = measta > I mm, vible grossly or with dissecting micoscope
and histologilly confirmed
aTotal pulmonary metastases found, per mouse.c preveni Ofmlstis
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Table H Metastasis from primary tumour
Mean Number of Mean
number of mice with metastasis Mean
Treatmenr treatments metastase? grade" survival
Placebo 6.2 0.3 24/47 4.8 ±0.5 59.0 3.6
DOX-SL 6 mg kg-' 9.3 ± 0.5 3/23d 5.0 ± 0 88.7 ± 6.9e
'Placebo, saline. DOX-SL, doxorubicin in sterically stabilised liposomes. 'The
total quantity ofpulmonary metastases found was graded on a scale from 0 (no
metastases found bymicroscopic examination) to 5 (macroscopic metastases); see
Table I. cMean survival (days) from the first treatment. dSignifiCantly less than
placebo (P<0.005). eSignificantly greater than placebo (P<0.00).
the tumours grew more slowly and 18 tumours were removed
65.6 ± 5.2 days after detection at an average size of
0.9 ± 0.07 cm3. Five tumours were reduced to unpalpable size
after 4-8 treatments, and were not found at necropsy
16.6 ± 2.3 weeks (range 8-22) after the first treatment. The
mice were observed for signs of cachexia, indicating pul-
monary metastatic tumour growth, for up to 6 weeks after
surgery. The mice tolerated the weekly treatments with
6 mg kg-' DOX-SL, experiencing only a transient average
weight loss of less than 5% during the course of injections.
The mice all recovered their weight within 3 weeks of the last
injection. The average weight of the untreated mice remained
stable during the study. Histological examination of the
hearts found no clear evidence of myocardial necrosis or
atrophy in the treated animals. The mean white cell counts in
the treated animals were within normal ranges at the time of
euthanasia.
Because pulmonary metastases develop from a high propor-
tion of primary C3HlHe mammary carcinomas this tumour
system was used as a model to test the known therapeutic
efficacies of DOX-SL against mouse mammary carcinomas
(Vaage et al., 1993) in a prophylactic programme against
metastasis. Prophylactic treatments were started when the
tumours were large enough that there was a high probability
that cells were being shed into the circulation and were
possibly also at an early stage of metastatic growth. SLs
containing the naturally fluorescing doxorubicin can be seen
by laser microscopy to have been taken up by all circulating
nucleated cells a few seconds after i.v. injection (unpublished
observation), and to have passed into established tumours in
minutes (Vaage et al., 1994). Stealth liposomal drugs in the
circulation would therefore be able to prevent metastasis as
well as inhibit the growth of micrometastases. The results
presented in Table II show that the prophylactic treatments
with liposome-encapsulated doxorubicin from the time of
primary tumour diagnosis resulted in a significant reduction
in the expected development of metastases. Considering the
mild systemic toxic side-effects (temporary weight loss) of
DOX-SL, the prophylactic benefits observed are encouraging
and may have clinical relevance. Empty liposomes were
found to have no therapeutic effect on mouse mammary
tumour growth (Vaage et al., 1992).
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